AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 4 analysts
Fundamentals
Fundamentals institutional score is 59 using EVA spread proxy -1.1%; growth durability 82.8.
Valuation
Valuation institutional score is 85 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 85 using mean target upside 50.7%; dispersion penalty 14.4; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 40 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 7 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. valuation and analyst consensus provide support, while technical structure and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 17.9% below historical median. Valuation is declining — currently in the strongly undervalued zone (z-score: -1.19). Confidence: 85%.
Live forward EPS implies next-12-month EPS of ₹45.25. Applying the stock's normalized valuation corridor produces a fair range of ₹913.14 to ₹1,151.16, with base value near ₹1,025.82 (+78.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹45.25
Forward P/E
12.7x
Base Fair Value
₹1,025.82
Fair Range
₹913.14 - ₹1,151.16
Upside To Base
+78.3%
Estimate Source
Live forward EPS
Growth Estimate
+102.1%
5Y Average
20.65
Current
18.62
Overvalued
25.44
Undervalued
20.18
5Y Average
9.23
Current
8.32
Overvalued
10.40
Undervalued
7.74
5Y Average
2.59
Current
2.34
Overvalued
2.98
Undervalued
2.20
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
YATHARTH HOSP & TRA C S L YATHARTHHospitals & Diagnostic Centres | +54.0% | 13.2% | 45.0x Undervalued | -29% vs avg | +22.0% |
NEPHROCARE HEALTH SERV L NEPHROPLUSHospitals & Diagnostic Centres | +22.2% | 8.1% | 82.4x Premium | +29% vs avg | +44.1% |
KRSNAA DIAGNOSTICS LTD trades at a discount (18.6x vs peer avg 63.7x), suggesting potential undervaluation relative to the Hospitals & Diagnostic Centres cohort. Peers include YATHARTH HOSP & TRA C S L, NEPHROCARE HEALTH SERV L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹173 CrMar 2026Latest net profit
₹43 CrMar 2026Latest EPS
₹13.37Mar 2026Net margin
33.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 116 | 132 | 147 | 152 | 159 | 163 | 179 | 165 | 175 | 176 | 183 | 159 | 173 |
| Expenses + | 91 | 100 | 116 | 113 | 116 | 120 | 126 | 117 | 121 | 126 | 125 | 112 | 116 |
| Operating Profit | 25 | 32 | 31 | 38 | 43 | 43 | 52 | 48 | 53 | 50 | 58 | 48 | 57 |
| OPM % | 22% | 24% | 21% | 25% | 27% | 26% | 29% | 29% | 31% | 29% | 32% | 30% | 33% |
| Other Income + | 6 | 4 | 4 | 4 | 4 | 7 | 5 | 9 | 4 | 4 | 4 | 4 | 31 |
| Interest | 2 | 2 | 3 | 4 | 7 | 5 | 6 | 6 | 7 | 6 | 8 | 8 | 12 |
| Depreciation | 15 | 16 | 18 | 21 | 18 | 21 | 22 | 23 | 22 | 22 | 23 | 23 | 22 |
| Profit before tax | 14 | 19 | 14 | 17 | 22 | 24 | 28 | 28 | 29 | 26 | 31 | 21 | 54 |
| Tax % | 17% | 18% | 20% | 20% | 17% | 23% | 23% | 24% | 28% | 26% | 24% | 22% | 20% |
| Net Profit + | 12 | 15 | 11 | 14 | 18 | 18 | 22 | 22 | 21 | 20 | 23 | 16 | 43 |
| EPS in Rs | 3.76 | 4.86 | 3.60 | 4.21 | 5.70 | 5.63 | 6.80 | 6.69 | 6.53 | 6.03 | 7.16 | 5.08 | 13.37 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026 And Fund Raising.
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Update On Himachal Tender
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018